Daewoong Pharmaceutical is hosting a web symposium to highlight the shift towards continuous glucose monitoring (CGM) technology, aiming to modernise diabetes care with insights from international clinical experiences and new treatment trends for Korean clinicians.
Daewoong Pharmaceutical said it will stream a web symposium on Wednesday through its Dr.Ville medical information platform, focusing on a shift in blood sugar management towards continuous glucose monitoring, or CGM. The company said the session is designed to help Korean clinicians follow newer treatment trends that use sensors worn on the skin to track glucose levels continuously, rather than relying only on finger-prick testing. According to Aju News, the format gives doctors a clearer picture of daily fluctuations in blood sugar.
The event will be chaired by Choi Sung-hee of Bundang Seoul National University Hospital, with presentations from Min Se-hee of Asan Medical Centre and Mototsugu Nagao of Tokyo Women’s Medical University. Daewoong Pharmaceutical said Nagao was invited to share recent Japanese clinical experience, where wider insurance coverage has helped CGM move into routine care for not only people with type 1 diabetes but also patients with type 2 diabetes who use insulin. Min is due to outline the U.S. Food and Drug Administration’s guidance on integrated CGM devices, including approved uses, accuracy by glucose range and practical issues around reliability in everyday practice.
Choi is expected to lead discussion on the latest evidence and how CGM data can be turned into meaningful lifestyle and self-management support for patients. Daewoong Pharmaceutical’s ETC marketing chief, Park Hyung-chul, said diabetes care is increasingly moving beyond simple readings towards helping people understand their own data and manage their condition more actively. The company also said it was recently selected as a partner in Seoul’s “Blood Sugar Catch 9988” public support scheme, which targets 1,000 Seoul residents identified as pre-diabetic through community metabolic syndrome screening.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
